SpectraCure AB (publ) (SPEC.ST)
SEK 1.7
(-2.41%)
SEK 1.7
(-2.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -50.23 Million SEK | 44.48% |
| 2022 | -90.48 Million SEK | 27.49% |
| 2021 | -124.78 Million SEK | 17.83% |
| 2020 | -151.87 Million SEK | -219.79% |
| 2019 | -47.49 Million SEK | -5.36% |
| 2018 | -45.07 Million SEK | -1747.21% |
| 2017 | -2.44 Million SEK | -539.34% |
| 2016 | -381.66 Thousand SEK | 95.32% |
| 2015 | -8.15 Million SEK | -4364.02% |
| 2014 | -182.65 Thousand SEK | 59.28% |
| 2013 | -448.57 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -41.64 Million SEK | 17.11% |
| 2024 Q2 | -29.75 Million SEK | 28.55% |
| 2023 Q1 | -79.6 Million SEK | 12.02% |
| 2023 FY | -50.23 Million SEK | 44.48% |
| 2023 Q4 | -50.23 Million SEK | 9.97% |
| 2023 Q3 | -55.79 Million SEK | 9.24% |
| 2023 Q2 | -61.47 Million SEK | 22.77% |
| 2022 Q1 | -117.21 Million SEK | 6.07% |
| 2022 FY | -90.48 Million SEK | 27.49% |
| 2022 Q4 | -90.48 Million SEK | 8.59% |
| 2022 Q3 | -98.98 Million SEK | 6.71% |
| 2022 Q2 | -106.09 Million SEK | 9.49% |
| 2021 FY | -124.78 Million SEK | 17.83% |
| 2021 Q1 | -147.9 Million SEK | 2.62% |
| 2021 Q2 | -137.36 Million SEK | 7.12% |
| 2021 Q3 | -131.38 Million SEK | 4.35% |
| 2021 Q4 | -124.78 Million SEK | 5.02% |
| 2020 Q1 | -44.12 Million SEK | 7.1% |
| 2020 Q2 | -36.01 Million SEK | 18.39% |
| 2020 Q3 | -153.62 Million SEK | -326.63% |
| 2020 Q4 | -151.87 Million SEK | 1.14% |
| 2020 FY | -151.87 Million SEK | -219.79% |
| 2019 Q2 | -23.24 Million SEK | 43.27% |
| 2019 Q1 | -40.96 Million SEK | 9.12% |
| 2019 FY | -47.49 Million SEK | -5.36% |
| 2019 Q4 | -47.49 Million SEK | -151.22% |
| 2019 Q3 | -18.9 Million SEK | 18.65% |
| 2018 Q2 | -7.07 Million SEK | 43.63% |
| 2018 FY | -45.07 Million SEK | -1747.21% |
| 2018 Q4 | -45.07 Million SEK | -1962.93% |
| 2018 Q3 | -2.18 Million SEK | 69.12% |
| 2018 Q1 | -12.55 Million SEK | -414.39% |
| 2017 Q3 | -6.34 Million SEK | 24.01% |
| 2017 Q1 | -11.12 Million SEK | -2815.71% |
| 2017 Q2 | -8.35 Million SEK | 24.92% |
| 2017 Q4 | -2.44 Million SEK | 61.57% |
| 2017 FY | -2.44 Million SEK | -539.34% |
| 2016 Q1 | -5.85 Million SEK | 28.19% |
| 2016 FY | -381.66 Thousand SEK | 95.32% |
| 2016 Q3 | -656.96 Thousand SEK | 78.76% |
| 2016 Q4 | -381.66 Thousand SEK | 41.9% |
| 2016 Q2 | -3.09 Million SEK | 47.18% |
| 2015 Q3 | -4.94 Million SEK | -971.16% |
| 2015 Q4 | -8.15 Million SEK | -64.98% |
| 2015 Q1 | -41.91 Thousand SEK | 77.05% |
| 2015 Q2 | -461.39 Thousand SEK | -1000.73% |
| 2015 FY | -8.15 Million SEK | -4364.02% |
| 2014 FY | -182.65 Thousand SEK | 59.28% |
| 2014 Q4 | -182.65 Thousand SEK | 0.0% |
| 2014 Q1 | 448.57 Thousand SEK | 0.0% |
| 2013 FY | -448.57 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | -42.917% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 104.094% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 104.094% |
| Arcoma AB | -1.12 Million SEK | -4353.369% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 145.716% |
| BICO Group AB (publ) | 927.9 Million SEK | 105.414% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 139.002% |
| CellaVision AB (publ) | -56.94 Million SEK | 11.78% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -237.662% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -494.119% |
| C-Rad AB (publ) | -127.6 Million SEK | 60.632% |
| Duearity AB (publ) | 10.23 Million SEK | 590.998% |
| Dignitana AB (publ) | 13.07 Million SEK | 484.14% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 4.679% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.929% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | -43.308% |
| Iconovo AB (publ) | -10.75 Million SEK | -367.061% |
| Integrum AB (publ) | -10.47 Million SEK | -379.491% |
| Luxbright AB (publ) | -13.83 Million SEK | -263.134% |
| Mentice AB (publ) | -49.56 Million SEK | -1.352% |
| OssDsign AB (publ) | -162.78 Million SEK | 69.141% |
| Paxman AB (publ) | -11.41 Million SEK | -340.224% |
| Promimic AB (publ) | -50.32 Million SEK | 0.177% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 363.419% |
| SciBase Holding AB (publ) | -27.32 Million SEK | -83.846% |
| ScandiDos AB (publ) | -1.53 Million SEK | -3181.123% |
| Sectra AB (publ) | -772.85 Million SEK | 93.5% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 77.858% |
| Senzime AB (publ) | -139.54 Million SEK | 64.001% |
| Stille AB | -178.5 Million SEK | 71.858% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 104.091% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 76.597% |